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Progressive heart failure in children and young adults is a serious
problem, with an overall mortality of 7% in the United States [1]. In
the past, the vast majority of children with heart failure had either car-
diomyopathy or myocarditis, however, with improved surgical survival
of high risk neonates with congenital heart disease, the incidence of
heart failure due to structural heart disease has increased dramatically.
There are critical differences in the response to injury between the
young and the mature heart the potential for regeneration is greater
in the former, in comparison to the more limited response in the older
adult heart. Aswell, the etiologies of pediatric heart failure are less likely
to lead to large areas of ﬁbrosis, which is typical of the cardiomyopathy
seen aftermyocardial infarction in adults [2]. Notably, pressure overload
in the right ventricle in pediatric hearts results in a 3-fold increase in
cardiac progenitors and suggests that an adaptive response is present
in children, yet this innate regeneration is not sufﬁcient to overcome
the challenges of severe heart disease [3]. Genetic, environmental, or
metabolic challenges can accelerate progressive heart failure despite
the best supportive surgical and medical treatment. Unfortunately, the
supply of available pediatric transplant donor hearts is a major limita-
tion and even patients who undergo successful transplant trade cardiac
dysfunction for the life-long complications of immunosuppression.
Therefore, to provide new innovative strategies for these patients, re-
generative technologies need to be fully evaluated as a transformative
strategy. There is a rapidly growing list of cell-based technologies that
could be re-purposed for pediatric heart disease applications [4], with
appropriate concerns for safety in this unique population. The future
of cardiac regenerative medicine for pediatrics is being shaped based
on emerging clinical trials and rapid advances in our knowledge of car-
diac progenitor cell biology. This review highlights the current knowl-
edge in the new ﬁeld of cell-based regenerative therapies and the
potential these strategies offer children with severe heart disease.⁎ Corresponding author at: Department of Medicine, Mayo Clinic, 200 First Street, SW,
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Disease
Withmore than a decade of dedicated effort, the science of cardiac re-
generative medicine has provided the medical community with
substantial data on the advantages and limitations of cell-based therapy,
e.g., bone marrow derived stem cells (BMSC) in adults with ischemic
heart disease. Having established a ﬁrm foundation focused on
important safety proﬁles, clinical trials have demonstrated no evidence
of increased arrhythmogenicity, acute cardiac toxicity, or tumor forma-
tion [5–10]. Depending on the characteristics of the patient population
studied and the cell-type or delivery method used, cardiac performance
has improved, but so far with only modest efﬁcacy. Therefore, the focus
on next-generation products and delivery strategies will need to
continue to improve these early results. Of note, one of the most
powerful associations in these studies has been the age of the patient as
younger patients are more likely to have superior outcomes following
cell-based delivery [11,12]. When cell-based therapies have been scruti-
nized in the laboratory, it is becoming apparent that the mechanisms by
which they enhance regeneration are largely through a paracrinemediat-
ed augmentation of the limited underlying innate regenerative response
of the myocardium, rather than by long-term survival and integration of
existing cells [13–16]. Indeed, studies have shown that the majority of
stem cells will be gonewithin amonth of administration, despite their ef-
fect on improving cardiac function [17]. Therefore, providing these para-
crine mediated effects at a time which will provide maximal beneﬁt
may be one of the predominant determinants that predicts optimal out-
comes. Alternative modalities, which may eventually have application
for the pediatric heart failure population, include the use of epicardial
bioengineered patches, which can be used for the longer-term delivery
of speciﬁc paracrine factors directly to injured myocardium [18].3. Cardiac Regenerative Medicine for Patients with Congenital Heart
Disease (CHD)
On the basis of early results in adult patients, the application of cell-
based therapies to pediatric patients is primed to open new therapeutice under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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heart. Experience with cell-based therapy in children with severe
heart disease is quite limited compared to the adult experience, and to
date no large clinical trials have been reported using cell-based therapy.
Many early reports have used bone marrow derived cells administered
via intracoronary infusion, in patients with either single ventricles or
dilated cardiomyopathy.
One of the initial examples of cell-based therapy in a pediatric
patient was a case report in a patient with dilated cardiomyopathy,
reported in 2009 [19]. An intracoronary injection of autologous BM-
MNCs (bone marrow-mononuclear cells) was associated in a doubling
of LV ejection fraction from the 20% range to 40% range after a period
of 6 months. Another case report of cell-based infusion was in an 11-
month-old patient with congenital heart disease. There were no early
complications or adverse events at 3 months follow-up. Magnetic
resonance imaging showed an improvement of the calculated ejection
fraction of the systemic right ventricle, from 22% to 44%, along with a
reduction of end-diastolic and end-systolic volumes, indicating reverse
modeling. The brain natriuretic peptide levels decreased from
2500 pg/ml to 132 pg/ml [20]. In a larger series, bone marrow-derived
mononuclear cells were delivered intracoronary in 9 children with
end-stage heart failure, 6 of whom suffered from dilated cardiomyopa-
thy and 3 from congenital heart disease. Starting with a bone marrow
aspirate, autologous cells were processed and infused on the same
day. A stop-ﬂow technique was used for intracoronary delivery and
was reported to cause transient ST-segment changes. There were no
procedure-related unexpected adverse events. Three patients with
dilated cardiomyopathy showed improvement in brain natriuretic pep-
tide serum levels and in ejection fraction throughout intermediate-term
follow-up [21]. These studies suggest the potential for a meaningful
regenerative response, with low acute risk, after the delivery of autolo-
gous mononuclear cells for pediatric heart disease. However, as none of
these studies were performed with controls, their ﬁndings can only be
regarded as the ﬁrst step.
A Phase I study examining autologous cell-based therapy in
congenital heart disease using intracoronary infusions of cardiac de-
rived cells (the TICAP trial) was completed in 2013 [12,22]. In this
non-randomized controlled study, 14 consecutive patients with HLHS
were prospectively assigned to receive intracoronary cardiac-derived
cells cultured from a cardiac biopsy one month after cardiac surgery
(n = 7), followed by 7 control patients who received standard care
alone. There were no serious adverse events within the 36 month
follow-up period. Echocardiography demonstrated an improvement in
RVEF compared with the case controls (+8% ± 4.7% vs +2.2% ±
4.3%). Based on these encouraging results, the ﬁrst randomized-
controlled, prospective phase 2 clinical trial is currently being conduct-
ed at Okayama University in Japan. The Cardiac Progenitor Cell Infusion
to Treat Univentricular Heart Disease (PERSEUS-NCT01829750) trial
has been designed to assess the efﬁcacy of intracoronary infusion of
cardiac-derived cells (CDCs) in young patients (up to 20 years of age)
with univentricular heart disease (hypoplastic left heart syndrome,
single right ventricle and single left ventricle). A total of 34 patients
will be randomly assigned 1:1 to the treated or control group. Patients
included in this study will have had a cardiac biopsy at the time of
surgery.
Other ongoing clinical trials using autologous cells in pediatric
heart disease include phase I trials at the Mayo Clinic (BM) and at
Duke University (NCT01445041). The Mayo Clinic study is using au-
tologous bone marrow derived mononuclear cells to be infused into
the coronary circulation of failing Fontan patients with a systemic
right ventricle. The primary endpoints will be cardiac performance
before and after cell delivery. The Duke study is evaluating the safety
and feasibility of collecting and intravenous infusion of autologous
umbilical cord blood in newborns with HLHS at the time of cardiac
surgery. Endpoints will include neurological improvement and
cardiac performance.In addition to these intracoronary infusion studies, theMayo Clinic is
leading a studywith theUniversity of Oklahoma to determine the safety
and feasibility of intramyocardial delivery of autologous mononuclear
cells in high-risk congenital heart disease patients at the time of a
planned Glenn operation for HLHS (NCT01883076). The main goal of
this study is to determine the safety proﬁle and feasibility of
intramyocardial delivery of autologous mononuclear cells (MNCs) for
childrenwith structural heart disease as compared to a parallel observa-
tional study (NCT01708863) with identical inclusion and exclusion
criteria and prospective follow-up in an open study design. The ﬁrst
case report of direct intramyocardial injection of umbilical cord blood
derivedMNCs in an infantwithHLHShas been published [23]. Umbilical
cord blood was collected at the time of delivery, and the MNCs fraction
isolated and stored. Cells were then injected directly into the right
ventricular myocardium at the time of the Stage II (Glenn shunt)
palliation. No adverse events occurred either at the time of infusion or
throughout the post-procedural follow-up. Transthoracic echocardiog-
raphy at 3 months showed improvement in right ventricular systolic
function, with an ejection fraction of 50%, increased from 30 to 35% at
baseline prior to surgery.
Related to the published intramyocardial delivery strategy, the Uni-
versity of Miami is planning a study (NCT02398604) focused on HLHS
pediatric patients to deliver allogeneic mesenchymal stem cells
(MSCs), targeting an enrollment of 30 patients. The ﬁrst 10 patients
will receive allogeneic MSCs to determine feasibility and safety. The
next 20 HLHS patients will be randomized to the treatment and control
arms in a 1:3 ratio, respectively. The major difference between this
study and those above is that it will be the ﬁrst use of allogeneic cells
in a pediatric population.
4. Translational Research: Cell-based EmergingTechnologies for Car-
diac Regeneration in Pediatric Heart Disease
As clinical trials are ramping up in the early stages for pediatric heart
disease, pre-clinical studieswill become increasingly important to assist
in determining valid clinical endpoints for Phase III studies. Given the
differences between the etiologies of pediatric and adult heart disease,
reviewed above, pre-clinical studies will be required to optimize the
matching of regenerative technologies with speciﬁc pediatric patient
cohorts. Pre-clinical studies [24–27] have begun to speciﬁcally test
cell-based regenerative products from a wide variety of cell sources
including bone marrow, cord blood, peripheral blood and cardiac-
derived cells. Beyond the ﬁrst-generation of cell-based products, there
is a growing list of cells, growth factors, and genetic engineering strate-
gies that have been pioneered in adult patients [28]. Given the much
more limited number of pediatric patients with heart failure overall, it
will be important to learn from these adult studies as we prioritize the
next steps for our pediatric patients. Thus, the importance of pre-
clinical pediatric model systems to compare cell-based products head
to head in the most clinically relevant models.
Current scientiﬁc understanding of cardiac regeneration highlights
an age-dependent process of cardiomyocyte renewal that is evolution-
arily conserved to various degrees across species [29]. The transition
from the fetal environment, which is permissive to cardiac regeneration,
to the post-natal environment, where regeneration is markedly re-
duced, will require further study to determine factors, e.g., alterations
in oxygen tension, levels of reactive oxygen species (ROS) production
and their effects on regenerative gene expression in the mammalian
heart [30,31]. This self-renewal appears to be predominately due to
existing cardiomyocyte successfully undergoing cytokinesis rather
than generation of new cardiomyocytes from a resident stem cell
reservoir, as is the case in skeletal muscle [32]. Although this process
slows after birth to approximately 1% cellular renewal per year, there
is a further decline in late adolescence/early adulthood that suggests
that the capacity to reactivate this regeneration may be increased in
children compared to older adults [33]. Future regenerative strategies
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function of the young heart, augmenting basal levels of cardiac self-
renewal, and bioengineering additional cardiomyocytes for replace-
ment of tissue that is dysfunctional or even lacking in the case of
many congenital heart diseases.
5. Caveats Unique to the Pediatric Population
Although studies have so far, fortunately, demonstrated the general
safety of cell infusions or direct intramyocardial injection in children,
the sample size in these studies have been quite small. Serious compli-
cations that occur with low frequency may not be detected until larger
clinical trials are performed, which is a difﬁcult task in the pediatric
population. Children treated with such therapies will also be exposed
to many decades of potential risk compared to most adults. This could
theoretically increase the risk for the development of cell-therapy-
related arrhythmias or teratomas/malignancies in our youngest
patients. Long-term follow-up has a totally different deﬁnition for a 5-
year-old than it does for a 65 year-old. Finally, the selection of
appropriate controls will be critical, especially given the large variance
in indices of cardiac function that can occur naturally in a population
of patients with cardiomyopathy or congenital heart disease.
6. Conclusion
Cell-based therapies for pediatric patients with heart failure have
enormous potential to usher in a new paradigm of treatment. The suc-
cess of these therapies in the pediatric population may be enhanced
by the lack of large areas of infarct scarredmyocardium typical of adults
with ischemic heart disease, aswell as the enhanced (although still lim-
ited) ability of the young heart for innate regeneration. Ongoing clinical
and pre-clinical studies will inform our understanding of the basic
cellular and molecular biology of these therapies, and help determine
the appropriate clinical endpoints, in order to optimize regenerative
potential in the pediatric setting. Ultimately, successful regenerative
therapies will likely combine multiple components, such as priming
pluripotent stem cells for cardiogenesis with chemokines and growth
factors, efﬁciently delivering cells directly into diseased heart muscle
to minimize cell loss, augmenting regenerative potential with repeated
dosing, and stabilizing themicroenvironmentwith biomaterials for sus-
tainable improvements in cardiac structure and function. Innovation is
always debated and never the product of a single attempt, but rather
an iterative process of reﬁnement through scientiﬁc exploration. The
challenge for the ﬁeld of pediatric heart disease regeneration is to
build synergy between clinical practice and discovery science to
prioritize the people, processes, and technology with a focus on life-
long healthy outcomes.
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